Systemic levels of ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis

Immunopharmacology and Immunotoxicology

Volumn 34, Issue 6, 2012, Pages 1047-1053

  Yalcin, Arzu Didem ^a   Gumuslu, Saadet ^b   Parlak, Gizem Esra ^b   Bisgin, Atil ^b   Yildiz, Mustafa ^c   Kargi, Aysegül ^c   Gorczynski, Reginald M ^d  

^a Antalya Education and Research Hospital   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

^c Akdeniz University Hospitals and Clinics ^*  (Turkey)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Allergic asthma; Allergic rhinitis; Anti IgE; Ceruloplasmin oxidase activity; High sensitive CRP; Omalizumab; Skin prick test

Indexed keywords

C REACTIVE PROTEIN; CERULOPLASMIN; CERULOPLASMIN OXIDASE; DESLORATADINE; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; OMALIZUMAB; UNCLASSIFIED DRUG;

ADULT; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; CERULOPLASMIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; PRICK TEST; PRIORITY JOURNAL; SKIN TEST; SUBCUTANEOUS IMMUNOTHERAPY;

ADULT; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; C-REACTIVE PROTEIN; CERULOPLASMIN; FEMALE; HUMANS; MALE; RHINITIS, ALLERGIC, PERENNIAL; TIME FACTORS;

EID: 84866080123     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2012.697902     Document Type: Article

References (38)

1. Biological products: allergenic extracts: implementation of efficacy review. Federal register, Food and Drug Administration. 1985; 21 CRF Parts 600, 610 and 680 (Docket no. 81N-0096).
2. Yalcin, A.D., Ozdemir, L., Polat, H.H. Evaluation of sociodemographic characteristics of patients receiving specific immunotherapy in Antalya. Respirology 2011, 16(2), 191.
3. Takemura, M., Matsumoto, H., Niimi, A., Ueda, T., Matsuoka, H., Yamaguchi, M., Jinnai, M., Muro, S., Hirai, T., Ito, Y., Nakamura, T., Mio, T., Chin, K., Mishima, M. High sensitivity C-reactive protein in asthma. Eur Respir J 2006, 27, 908-912.
4. National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services. Expert panel report 3: guidelines for the diagnosis and management of asthma. Section 2, p. 1. 2007. Available at: http://www.nhlbi.nih. gov/guidelines/asthma/asthgdln.htm. Accessed April 13, 2010.
5. Ayres, J.G., Higgins, B., Chilvers, E.R., Ayre, G., Blogg, M., Fox, H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-tosevere) allergic asthma. Allergy 2004, 59, 701-708.
6. Cornwell W.D., Kim, V., Song, C., Rogers, T.J. Pathogenesis of Inflammation and Repair in Advanced COPD. Semin Respir Crit Care Med 2010, 31(3), 257-266.
7. Gumral, N., Naziroglu, M., Ongel, K., Beydilli, E.D., Ozguner, F., Sutcu, R., Caliskan, S., Akkaya, A. Antioxidant enzymes and melatonin levels in patients with bronchial asthma and chronic obstructive pulmonary disease during stable and exacerbation periods. Cell Biochem Funct 2009, 27, 276-283.
8. Yalcin, A.D., Gorczynski, R.M., Parlak, G.E., Kargi, A., Bisgin, A., Sahin, E., Kose, S., Gumuslu, S. Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment. Clin Lab 2012, 58, 89-96.
9. Sugiura, H., Ichinose, M. Oxidative and nitrative stress in bronchial asthma. Antioxid Redox Signal 2008, 10(4), 785-797.
10. Riedl, M.A., Nel, A.E. Importance of oxidative stress in the pathogenesis and treatment of asthma. Curr Opin Allergy Clin Immunol 2008, 8(1), 49-56.
11. Yalcin, A.D., Ozcaglar, H., Gumuslu, S. Investigation of amonium inhalation effects on rat respiratory mucosa by immunohistochemical and electron microscopy and effects of amonium inhalation on antioxidant enzyme activities in rat erythrocytes. (oral presentation Ythird prize winner in 9th International Otorhinolaryngology and Head Neck Surgery Congress) 8-10 April Ankara, Turkey, S34, 2010.
12. Gümüslü, S., Akbas, H., Alicigüzel, Y., Agar, A., Küçükatay, V., Yargiçoglu, P. Effects of sulfur dioxide inhalation on antioxidant enzyme activities in rat erythrocytes. Ind Health 1998, 36, 70-73.
13. Gümüslü, S., Korgun, D.K., Bilmen, S., Yargiçoglu, P., Agar, A. Effects of sulfur dioxide inhalation on plasma vitamin C and ceruloplasmin in ageing rats. Ind Health 2000, 38, 319-322.
14. Macintyre, G., Gutfreund, K.S., Martin, W.R., Camicioli, R., Cox, D.W. Value of an enzymatic assay for the determination of serum ceruloplasmin. J Lab Clin Med 2004, 144(6), 294301.
15. Giurgea, N., Constantinescu, M.I., Stanciu, R., Suciu, S., Muresan, A. Ceruloplasmin Y acutephase reactant or endogenous antioxidant? The case of cardiovascular disease. Med Sci Monit 2005, 11(2), RA48YRA51.
16. Savory, J., Hammond, J. (1980) Measurement of proteins in biological fluids.In: Sonnenwirth AC, Jarett L, eds. Gradwohl's Clinical Laboratory Methods and Diagnosis. St Louis: C.V. Mosby, 262-265.
17. Barber, E.F., Cousins, R.J. Interleukin-1Ystimulated induction of ceruloplasmin synthesis in normal and copper-deficient rats. J Nutr 1988, 118, 375-381.
18. Kennedy, T., Ghio, A.J., Reed, W., Samet, J., Zagorski, J., Quay, J., Carter, J., Dailey, L., Hoidal, J.R., Devlin, R.B. Copper-dependent inflammation and nuclear factor-kappaB activation by particulate air pollution. Am J Respir Cell Mol Biol 1998, 19, 366-378.
19. Ramadori, G., Van Damme, J., Rieder, H., Meyer zum Büschenfelde, K.H. Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factoralpha. Eur J Immunol 1988, 18, 1259-1264.
20. Schosinsky, K.H., Lehmann, H.P., Beeler, M.F. Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 1974, 20, 1556-1563.
21. Göçmen, A.Y., Sahin, E., Semiz, E., Gümüslü, S. Is elevated serum ceruloplasmin level associated with increased risk of coronary artery disease? Can J Cardiol 2008, 24(3), 209212.
22. Chen, C., Arjomandi, M., Balmes, J., Tager, I., Holland, N. Effects of chronic and acute ozone exposure on lipid peroxidation and antioxidant capacity in healthy young adults. Environ Health Perspect 2007, 115, 1732-1737.
23. Islam, T., McConnell, R., Gauderman, W.J., Avol, E., Peters, J.M., Gilliland, F.D. Ozone, oxidant defense genes, and risk of asthma during adolescence. Am J Respir Crit Care Med 2008, 177, 388-395.
24. Spannhake, E.W., Reddy, S.P., Jacoby, D.B., Yu, X.Y., Saatian, B., Tian, J. Synergism between rhinovirus infection and oxidant pollutant exposure enhances airway epithelial cell cytokine production. Environ Health Perspect 2002, 110, 665-670.
25. Blomberg, A. Airway inflammatory and antioxidant responses to oxidative and particulate air pollutants - experimental exposure studies in humans. Clin Exp Allergy 2000, 30, 310-317.
26. Li, N., Xia, T., Nel, A.E. The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles. Free Radic Biol Med 2008, 44, 1689-1699.
27. Gao, M., Singh, A., Macri, K., Reynolds, C., Singhal, V., Biswal, S., Spannhake, E.W. Antioxidant components of naturally-occurring oils exhibit marked anti-inflammatory activity in epithelial cells of the human upper respiratory system. Respir Res 2011, 12, 92.
28. Pradhan, A.D., Manson, J.E., Rifai, N., Buring, J.E., Ridker, P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286, 327-334.
29. Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P., Hennekens, C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336, 973-979.
30. Ridker, P.M., Hennekens, C.H., Buring, J.E., Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342, 836-843.
31. Pepys, M.B., Baltz, M.L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983, 34, 141-212.
32. Ridker, P.M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103, 1813-1818.
33. Jousilahti, P., Salomaa, V., Hakala, K., Rasi, V., Vahtera, E., Palosuo, T. The association of sensitive systemic inflammation markers with bronchial asthma. Ann Allergy Asthma Immunol 2002, 89, 381-385.
34. Büyüköztürk, S., Gelincik, A.A., Genç, S., Koçak, H., Oneriyidogan, Y., Erden, S., Dal, M., Colakoglu, B. Acute phase reactants in allergic airway disease. Tohoku J Exp Med 2004, 204, 209-213.
35. Dodig, S., Richter, D., Zrinski-Topic, R. Inflammatory markers in childhood asthma. Clin Chem Lab Med 2011, 49, 587-599.
36. Djukanovic, R., Wilson, S.J., Kraft, M., Jarjour, N.N., Steel, M., Chung, K.F., Bao, W., Fowler-Taylor, A., Matthews, J., Busse, W.W., Holgate, S.T., Fahy, J.V. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004, 170, 583-593.
37. Sadowska-Woda, I., Sychta, B., Rachel, M., Bieszczad-Bedrejczuk, E. Protective effect of desloratadine against oxidative stress in human erythrocytes in vitro. Environ Toxicol Pharmacol 2010, 30, 141-146.
38. Alzoghaibi, M.A., Bahammam, A.S. Lipid peroxides in stable asthmatics receiving inhaled steroids and long-acting beta2-agonists. Respirology 2007, 12, 439-442.